Makishima H, Saiki R, Nannya Y et al. Germ line DDX41 mutations define a unique subtype of myeloid neoplasms. Blood (2023) 141 (5): 534–549. Résumé de l’article : Dans cette analyse rétrospective internationale, [...]
Chen GL, Onstad L, Martin PJ et al. Durable discontinuation of systemic therapy in patients affected by chronic graft-versus-host disease. Haematologica Vol. 108 No. 2 (2023): February, 2023. Résumé de l’article : [...]
Westin J, Davis RE, Feng L et al. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma. J Clin Oncol 41:745-755. Résumé de l’article : Cette essai [...]
Réf. Convergences.online/Hemato ; 3(4) : U17 Brown JR, Eichhorst B, Hillmen P et al. Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J [...]
Réf. : Convergences.online/Hemato ; 1 (13) : R65 de Botton S, Montesinos P, Schuh AC, et al. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase [...]
Réf. : Convergences.online/Hemato ; 1 (13) : R64 Guillet S, Loustau V, Boutin E, et al. Immune thrombocytopenia and pregnancy: an exposed/nonexposed cohort study. Blood. 2023 141(1):11-21. Résumé de l’article : Un total de [...]
Réf. Convergences.online/Hemato ; 3(3) : U16 Paiva B, Manrique I, Dimopoulos MA, Gay F, Min CK, Zweegman S, et al. MRD dynamics during maintenance for improved prognostication [...]
